AA
NGNE icon

ALPS Advisors’s Neurogene NGNE Stock Holding History

ALPS Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Sell
12,606
-115
-0.9% -$2.23K ﹤0.01% 982
2025
Q4 		$262K Buy
+12,721
New +$317K ﹤0.01% 951
2018
Q4 		– Sell
-2,076
Closed -$122K – 915
2018
Q3 		$122K Buy
2,076
+373
+22% +$22K ﹤0.01% 936
2018
Q2 		$90K Buy
1,703
+129
+8% +$33.6K ﹤0.01% 918
2018
Q1 		$443K Buy
1,574
+274
+21% +$75.7K ﹤0.01% 743
2017
Q4 		$306K Buy
1,300
+144
+12% +$33.7K ﹤0.01% 734
2017
Q3 		$328K Buy
1,156
+101
+10% +$29K ﹤0.01% 720
2017
Q2 		$297K Buy
1,055
+47
+5% +$13.4K ﹤0.01% 720
2017
Q1 		$336K Sell
1,008
-117
-10% -$41.1K ﹤0.01% 677
2016
Q4 		$372K Buy
+1,125
New +$302K ﹤0.01% 637
2016
Q2 		– Sell
-968
Closed -$171K – 633
2016
Q1 		$171K Sell
968
-166
-15% -$32.3K ﹤0.01% 607
2015
Q4 		$283K Buy
+1,134
New +$298K ﹤0.01% 654

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ALPS Advisors's NGNE Position: Q1 2026 in Review

ALPS Advisors reduced its Neurogene (NGNE) stake by 0.9% in Q1 2026, selling an estimated $2.23K and leaving 12,606 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

ALPS Advisors first reported a position in NGNE in Q4 2015 and has held it in 12 quarters since. The position peaked at $443K in Q1 2018. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • ALPS Advisors held 12,606 shares of Neurogene worth $254K as of Q1 2026.
  • ALPS Advisors sold 115 Neurogene shares in Q1 2026, an estimated $2.23K.
  • Neurogene made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #982 holding.
  • ALPS Advisors first reported a position in Neurogene in Q4 2015 and has held it in 12 quarters since.
  • ALPS Advisors's Neurogene position peaked at $443K in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.